Full Text
The Full Text of this article is available as a PDF (85.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baecklund E., Ekbom A., Sparén P., Feltelius N., Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998 Jul 18;317(7152):180–181. doi: 10.1136/bmj.317.7152.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Baecklund E., Ekbom A., Sparén P., Feltelius N., Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998 Jul 18;317(7152):180–181. doi: 10.1136/bmj.317.7152.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ekström Karin, Hjalgrim Henrik, Brandt Lena, Baecklund Eva, Klareskog Lars, Ekbom Anders, Askling Johan. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003 Apr;48(4):963–970. doi: 10.1002/art.10939. [DOI] [PubMed] [Google Scholar]
- Emery P., Panayi G., Symmons D., Brown G. Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition. Ann Rheum Dis. 1984 Jun;43(3):430–434. doi: 10.1136/ard.43.3.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Heeley E., Riley J., Layton D., Wilton L. V., Shakir S. A. Prescription-event monitoring and reporting of adverse drug reactions. Lancet. 2001 Dec 1;358(9296):1872–1873. doi: 10.1016/S0140-6736(01)06898-2. [DOI] [PubMed] [Google Scholar]
- Kwon Hyon J., Coté Timothy R., Cuffe Michael S., Kramer Judith M., Braun M. Miles. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003 May 20;138(10):807–811. doi: 10.7326/0003-4819-138-10-200305200-00008. [DOI] [PubMed] [Google Scholar]
- Lügering A., Schmidt M., Lügering N., Pauels H. G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001 Nov;121(5):1145–1157. doi: 10.1053/gast.2001.28702. [DOI] [PubMed] [Google Scholar]
- Martin R. M., Kapoor K. V., Wilton L. V., Mann R. D. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ. 1998 Jul 11;317(7151):119–120. doi: 10.1136/bmj.317.7151.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mellemkjaer L., Linet M. S., Gridley G., Frisch M., Møller H., Olsen J. H. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996 Sep;32A(10):1753–1757. doi: 10.1016/0959-8049(96)00210-9. [DOI] [PubMed] [Google Scholar]
- Rawlins M. D. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. J R Coll Physicians Lond. 1995 Jan-Feb;29(1):41–49. [PMC free article] [PubMed] [Google Scholar]
- Scott H. D., Rosenbaum S. E., Waters W. J., Colt A. M., Andrews L. G., Juergens J. P., Faich G. A. Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J. 1987 Jul;70(7):311–316. [PubMed] [Google Scholar]
- Van den Brande Jan M. H., Braat Henri, van den Brink Gijs R., Versteeg Henri H., Bauer Christiaan A., Hoedemaeker Inge, van Montfrans Catherine, Hommes Daan W., Peppelenbosch Maikel P., van Deventer Sander J. H. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003 Jun;124(7):1774–1785. doi: 10.1016/s0016-5085(03)00382-2. [DOI] [PubMed] [Google Scholar]
- ten Hove T., van Montfrans C., Peppelenbosch M. P., van Deventer S. J. H. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002 Feb;50(2):206–211. doi: 10.1136/gut.50.2.206. [DOI] [PMC free article] [PubMed] [Google Scholar]